Viral infections in pediatric brain tumor patients treated with targeted therapies.
CNS infection
SARS-CoV-2
brain tumor
pediatric
targeted therapies
viral infection
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
31
08
2022
received:
30
06
2022
accepted:
29
09
2022
pubmed:
30
10
2022
medline:
30
11
2022
entrez:
29
10
2022
Statut:
ppublish
Résumé
Brain tumors are the most common solid malignancies and the leading cause of cancer-related mortality in children. While numerous studies report on viral infections in children with hematologic malignancies and solid organ transplantation, epidemiologic data on the incidence and outcome of viral infections in pediatric patients with brain tumors treated with targeted therapies are still lacking. We retrospectively reviewed all children with brain tumors receiving targeted therapies in a primary or recurrent setting at the Medical University of Vienna from 2006 to 2021. Demographic variables, quantitative and qualitative parameters of possible infections, and treatment outcomes were recorded. In our cohort (n = 117), 36% of the patients developed at least one PCR-proven viral infection. Respiratory and gastrointestinal tract infections were most common, with 31% and 25%, respectively. Central nervous system (CNS) infections occurred in approximately 10%, with an almost equal distribution of varicella-zoster virus, John Cunningham virus (JCV), and enterovirus. Two patients tested PCR-positive for SARS-CoV-2 infection, with one virus-related death caused by a SARS-CoV-2-related acute respiratory distress syndrome. Patients receiving bevacizumab or mTOR inhibitors seem to have a greater susceptibility to viral infections. Pediatric patients with brain tumors receiving targeted therapies have a higher risk of viral infections when compared to children receiving conventional chemotherapy or the general population, and life-threatening infections can occur. Fast detection and upfront treatment are paramount to prevent life-threatening infections in immunocompromised children suffering from brain tumors receiving targeted therapies.
Sections du résumé
BACKGROUND
Brain tumors are the most common solid malignancies and the leading cause of cancer-related mortality in children. While numerous studies report on viral infections in children with hematologic malignancies and solid organ transplantation, epidemiologic data on the incidence and outcome of viral infections in pediatric patients with brain tumors treated with targeted therapies are still lacking.
OBJECTIVES/STUDY DESIGN
We retrospectively reviewed all children with brain tumors receiving targeted therapies in a primary or recurrent setting at the Medical University of Vienna from 2006 to 2021. Demographic variables, quantitative and qualitative parameters of possible infections, and treatment outcomes were recorded.
RESULTS
In our cohort (n = 117), 36% of the patients developed at least one PCR-proven viral infection. Respiratory and gastrointestinal tract infections were most common, with 31% and 25%, respectively. Central nervous system (CNS) infections occurred in approximately 10%, with an almost equal distribution of varicella-zoster virus, John Cunningham virus (JCV), and enterovirus. Two patients tested PCR-positive for SARS-CoV-2 infection, with one virus-related death caused by a SARS-CoV-2-related acute respiratory distress syndrome. Patients receiving bevacizumab or mTOR inhibitors seem to have a greater susceptibility to viral infections.
CONCLUSION
Pediatric patients with brain tumors receiving targeted therapies have a higher risk of viral infections when compared to children receiving conventional chemotherapy or the general population, and life-threatening infections can occur. Fast detection and upfront treatment are paramount to prevent life-threatening infections in immunocompromised children suffering from brain tumors receiving targeted therapies.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30065Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Tailor J, Jackson EM. Brain and spinal cord tumors in children. Pediatr Clin North Am. 2021;68(4):811-824. https://doi.org/10.1016/j.pcl.2021.04.007
Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr. 2019;23(3):261-273. https://doi.org/10.3171/2018.10.PEDS18377
Mueller T, Stucklin ASG, Postlmayr A, et al. Advances in targeted therapies for pediatric brain tumors. Curr Treat Options Neurol. 2020;22(12):43. https://doi.org/10.1007/s11940-020-00651-3
Dunkel IJ, Gardner SL, Garvin JH, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol. 2010;12(3):297-303. https://doi.org/10.1093/neuonc/nop031
Shih CS, Hale GA, Gronewold L, et al. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer. 2008;112(6):1345-1353. https://doi.org/10.1002/cncr.23305
Koskenvuo M, Rahiala J, Sadeghi M, et al. Viremic co-infections in children with allogeneic haematopoietic stem cell transplantation are predominated by human polyomaviruses. Infect Dis (Lond). 2017;49(1):35-41. https://doi.org/10.1080/23744235.2016.1210821
Soudani N, Caniza MA, Assaf-Casals A, et al. Prevalence and characteristics of acute respiratory virus infections in pediatric cancer patients. J Med Virol. 2019;91(7):1191-1201. https://doi.org/10.1002/jmv.25432
Ye X, Van JN, Munoz FM, et al. Noroviruses as a cause of diarrhea in immunocompromised pediatric hematopoietic stem cell and solid organ transplant recipients. Am J Transplant. 2015;15(7):1874-1881. https://doi.org/10.1111/ajt.13227
Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis. 2008;10(1):19-23. https://doi.org/10.1111/j.1399-3062.2007.00242.x
Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in children with cancer: report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer. 2021;124(4):754-759. https://doi.org/10.1038/s41416-020-01181-0
Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702. https://doi.org/10.1542/peds.2020-0702
Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC):a cohort study. Lancet Oncol. 2021;22(10):1416-1426. https://doi.org/10.1016/S1470-2045(21)00454-X
Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer. 2012;59(3):511-517. https://doi.org/10.1002/pbc.24006
Ward CL, Dempsey MH, Ring CJA, et al. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol. 2004;29(3):179-188. https://doi.org/10.1016/S1386-6532(03)00122-7
Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol. 2003;70(2):228-239. https://doi.org/10.1002/jmv.10382
Fry AM, Chittaganpitch M, Baggett HC, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS One. 2010;5(11):e15098. https://doi.org/10.1371/journal.pone.0015098
Lu X, Holloway B, Dare RK, et al. Real-time reverse transcription-PCR assay for comprehensive detection of human rhinoviruses. J Clin Microbiol. 2008;46(2):533-539. https://doi.org/10.1128/JCM.01739-07
Maertzdorf J, Wang CK, Brown JB, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol. 2004;42(3):981-986. https://doi.org/10.1128/JCM.42.3.981-986.2004
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
Watkins-Riedel T, Woegerbauer M, Hollemann D, Hufnagl P. Rapid diagnosis of enterovirus infections by real-time PCR on the LightCycler using the TaqMan format. Diagn Microbiol Infect Dis. 2002;42(2):99-105. https://doi.org/10.1016/s0732-8893(01)00330-3
Weseslindtner L, Hedman L, Wang Y, et al. Longitudinal assessment of the CXCL10 blood and urine concentration in kidney transplant recipients with BK polyomavirus replication-a retrospective study. Transpl Int. 2020;33(5):555-566. https://doi.org/10.1111/tri.13584
Aberle SW, Puchhammer-Stöckl E. Diagnosis of herpesvirus infections of the central nervous system. J Clin Virol. 2002;25(1):S79-S85. https://doi.org/10.1016/s1386-6532(02)00037-9
Fernandez C, Boutolleau D, Manichanh C, Mangeney N, Agut H, Gautheret-Dejean A. Quantitation of HHV-7 genome by real-time polymerase chain reaction assay using MGB probe technology. J Virol Methods. 2002;106(1):11-16. https://doi.org/10.1016/s0166-0934(02)00131-3
Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012;10(12):825-826.
Rolston KVI. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6(1):69-83. https://doi.org/10.1007/s40121-017-0146-1
Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):220-227. https://doi.org/10.1016/j.hemonc.2017.05.009
Gea-Banacloche JC, Wade JC. Improvements in the prevention and management of infectious complications after hematopoietic stem cell transplantation. Cancer Treat Res. 2009;144:539-573. https://doi.org/10.1007/978-0-387-78580-6_21
Young JAH. Management of infectious diseases in stem cell transplantation and hematologic malignancy. Infect Dis Clin North Am. 2019;33(2):xiii-xv. https://doi.org/10.1016/j.idc.2019.02.013
Young JAH, Logan BR, Wu J, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22(2):359-370. https://doi.org/10.1016/j.bbmt.2015.09.013
Alexandersson A, Koskenvuo M, Tiderman A, et al. Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation. Infect Dis (Lond). 2019;51(10):772-778. https://doi.org/10.1080/23744235.2019.1650198
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73. https://doi.org/10.1038/nri2216
Payne DC, Vinjé J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med. 2013;368(12):1121-1130. https://doi.org/10.1056/NEJMsa1206589
Avery RK, Lonze BE, Kraus ES, Marr KA, Montgomery RA. Severe chronic norovirus diarrheal disease in transplant recipients: clinical features of an under-recognized syndrome. Transpl Infect Dis. 2017;19(2):e12674. https://doi.org/10.1111/tid.12674
Ison MG, Hirsch HH. Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs. Clin Microbiol Rev. 2019;32(4):e00042-19. https://doi.org/10.1128/CMR.00042-19
Koskenvuo M, Möttönen M, Rahiala J, et al. Respiratory viral infections in children with leukemia. Pediatr Infect Dis J. 2008;27(11):974-980. https://doi.org/10.1097/INF.0b013e31817b0799
Christensen MS, Nielsen LP, Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. Pediatr Blood Cancer. 2005;45(7):945-951. https://doi.org/10.1002/pbc.20469
Lindblom A, Bhadri V, Söderhäll S, et al. Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol. 2010;47(3):234-237. https://doi.org/10.1016/j.jcv.2009.11.026
Srinivasan A, Gu Z, Smith T, et al. Prospective detection of respiratory pathogens in symptomatic children with cancer. Pediatr Infect Dis J. 2013;32(3):e99-e104. https://doi.org/10.1097/INF.0b013e31827bd619
Lin B, Kennedy B, McBride J, et al. Long-term morbidity of respiratory viral infections during chemotherapy in children with leukaemia. Pediatr Pulmonol. 2019;54(11):1821-1829. https://doi.org/10.1002/ppul.24456
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. https://doi.org/10.1182/blood.2020008824
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-791. https://doi.org/10.1158/2159-8290.CD-20-0422
André N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr Blood Cancer. 2020;67(7):e28392. https://doi.org/10.1002/pbc.28392
Hrusak O, Kalina T, Wolf J, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020;132:11-16. https://doi.org/10.1016/j.ejca.2020.03.021
Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-661. https://doi.org/10.1016/S2352-4642(20)30177-2
Ferrari A, Zecca M, Rizzari C, et al. Children with cancer in the time of COVID-19: an 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy. Pediatr Blood Cancer. 2020;67(8):e28410. https://doi.org/10.1002/pbc.28410
de Rojas T, Pérez-Martínez A, Cela E, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer. 2020;67(7):e28397. https://doi.org/10.1002/pbc.28397
Stephens RJ, Liang SY. Central nervous system infections in the immunocompromised adult presenting to the emergency department. Emerg Med Clin North Am. 2021;39(1):101-121. https://doi.org/10.1016/j.emc.2020.09.006
Rantakallio P, Leskinen M, von Wendt L. Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children. Scand J Infect Dis. 1986;18(4):287-294. https://doi.org/10.3109/00365548609032339
Ben Abid F, Abukhattab M, Ghazouani H, et al. Epidemiology and clinical outcomes of viral central nervous system infections. Int J Infect Dis. 2018;73:85-90. https://doi.org/10.1016/j.ijid.2018.06.008
de Ory F, Avellón A, Echevarría JE, et al. Viral infections of the central nervous system in Spain: a prospective study. J Med Virol. 2013;85(3):554-562. https://doi.org/10.1002/jmv.23470
Grahn A, Studahl M. Varicella-zoster virus infections of the central nervous system - prognosis, diagnostics and treatment. J Infect. 2015;71(3):281-293. https://doi.org/10.1016/j.jinf.2015.06.004
Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438. https://doi.org/10.1212/WNL.0b013e31828c2fa1
Pinto M, Dobson S. BK, and JC virus: a review. J Infect. 2014;68(1):S2-S8. https://doi.org/10.1016/j.jinf.2013.09.009
Demirbuğa A, Kaba O, Törün SH, Yıldız EP, Yücel E, Somer A. Progressive multifocal leukoencephalopathy in children with primary and secondary immune deficiency. Pediatr Allergy Immunol Pulmonol. 2021;34(3):109-111. https://doi.org/10.1089/ped.2020.1330
Karimi Dehcheshmeh L, Makvandi M, Timori A. Prevalence of human polyomavirus JC and BK in normal population. Asian Pac J Cancer Prev. 2020;21(10):2877-2882. https://doi.org/10.31557/APJCP.2020.21.10.2877
da Silva Nali LH, de Campose Centrone C, Urbano PR, et al. High prevalence of the simultaneous excretion of polyomaviruses JC and BK in the urine of HIV-infected patients without neurological symptoms in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54(4):201-205. https://doi.org/10.1590/s0036-46652012000400004
Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the era of targeted therapies: mapping the road ahead. Front Med. 2020;7:336. https://doi.org/10.3389/fmed.2020.00336
Garcia CA, Wu S. Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer. Cancer Invest. 2016;34(10):521-530. https://doi.org/10.1080/07357907.2016.1242009
Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(2):S53-S70. https://doi.org/10.1016/j.cmi.2018.02.009
Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (cell surface receptors and associated signaling pathways). Clin Microbiol Infect. 2018;24(2):S41-S52. https://doi.org/10.1016/j.cmi.2017.12.027
Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276(25):22382-22387. https://doi.org/10.1074/jbc.M100938200
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-1680. https://doi.org/10.1084/jem.177.6.1675
Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929-938. https://doi.org/10.1002/ana.24523